GPI SpA (GPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 31. Analyst Davide Longo from TP ICAP MIDCAP maintained a Buy rating on the stock and has a €20.00 price target.
Davide Longo has given his Buy rating due to a combination of factors that highlight GPI SpA’s strong financial performance and strategic growth initiatives. The company reported impressive revenue and EBITDA figures for FY24, surpassing expectations with a significant increase in the software segment, which now constitutes a larger portion of the revenue mix. This growth is attributed to both organic and external factors, showcasing the scalability of their business model.
Additionally, GPI SpA has improved its geographical diversification, with increased international exposure contributing to revenue growth. The company’s strategic acquisitions and the issuance of new bonds to finance further investments align with its industrial plan, supporting future growth prospects. The proposed dividend and positive outlook for revenue and EBITDA margins in the coming years further reinforce the Buy rating, as these elements indicate a robust financial position and potential for continued success.
GPI’s price has also changed moderately for the past six months – from EUR12.700 to EUR8.860, which is a -30.24% drop .